Isomorphic Labs raises $5 billion Series C led by Greenoaks and Sequoia
Isomorphic Labs, Demis Hassabis's AI drug discovery startup, has raised a $5 billion Series C co-led by Greenoaks and Sequoia, with Alphabet participating, three months after he left as Google DeepMind CEO.

Why it matters
- Isomorphic Labs raised a $5 billion Series C announced Tuesday, co-led by Greenoaks and Sequoia Capital with Alphabet participating.
- The round comes three-and-a-half months after Demis Hassabis stepped back as CEO of Google DeepMind.
- Drug discovery startups have raised a record $23.2 billion in 2026, per Dealroom.
- Isomorphic previously raised a $2.1 billion Series B in May.
- Anthropic launched an AI drug discovery program in June; OpenAI partnered with Novo Nordisk in April.
Isomorphic Labs, the artificial intelligence drug discovery startup founded by Demis Hassabis, has raised a $5 billion Series C, the company said on Tuesday. The round ranks among the largest private financings in the biotech-AI sector, and it lands three-and-a-half months after Hassabis stepped back as CEO of Google DeepMind, the AI lab he co-founded before Google acquired it in 2014.
The round was co-led by Greenoaks and Sequoia Capital, alongside Andreessen Horowitz, with investment from Alphabet, Google's parent company. Isomorphic will use the fresh funds to finance the design and development of new medicines using AI, the company said.
Who is behind Isomorphic Labs?
Hassabis has led Isomorphic as CEO since the startup spun out of DeepMind in 2021. The spin-out gave the founder a dedicated vehicle for applying AI to biology, separate from Google's broader research agenda. His departure from the DeepMind CEO role, announced earlier in 2026, freed him to run Isomorphic full time — and investors have now capitalized that bet at scale.
The Alphabet participation matters for a second reason. Google's parent was already positioned to benefit from Hassabis's work through its 2014 acquisition of DeepMind. Its renewed cheque in the Series C keeps the corporate tie intact even as Isomorphic operates as an independent startup.
What did Hassabis say about the round?
Hassabis framed the financing as validation of the company's founding thesis: that AI can compress the timelines of drug discovery by modeling biology at the molecular level.
"When we founded Isomorphic, our conviction was that biology could be understood and modelled at the most fundamental molecular level and radically accelerated through AI," Hassabis said.
He added that the capital has a specific, staged purpose: "This round enables us to accelerate our progress: building foundational biology models, deepening our systemic disease understanding, and driving our first therapeutic programs towards clinical trials to deliver tangible impact for patients."
The quote carries weight beyond rhetoric. Moving therapeutic programs into clinical trials is the point at which AI-designed drug candidates face regulatory and human testing — the most expensive and highest-failure stage of drug development. The $5 billion gives Isomorphic the balance sheet to reach it.
What is the company actually building?
Isomorphic is constructing two connected assets:
- A proprietary drug design engine built with AI
- A pipeline of therapeutic candidates designed using that engine
The company says this combination will help it deliver what it calls the next generation of medicines. No clinical-stage results, trial dates, or specific drug targets were disclosed in Tuesday's announcement, which centers on the financing itself.
The structural bet is familiar to anyone who followed DeepMind's AlphaFold work: that foundational models of biology, trained on molecular data, can outperform conventional chemistry pipelines in both speed and design precision. Isomorphic is the commercial application of that premise.
How large is the AI drug discovery funding wave?
The context is a record year. Drug discovery startups have raised $23.2 billion in 2026, according to deal-counting platform Dealroom — the highest figure on record for the category. Isomorphic's $5 billion Series C represents more than a fifth of that total in a single transaction.
The startup is also out-raising itself. Isomorphic last raised in May, with a $2.1 billion Series B. The new round more than doubles the company's previous financing in roughly half a year, a pace that suggests investor demand rather than company scarcity driven the valuation.
Where do OpenAI and Anthropic fit in?
Isomorphic is not competing alone. The frontier AI labs have moved into the same territory in 2026, as companies look to capitalize on advances in AI for pharmaceutical applications.
- Anthropic announced in June that it was launching an AI drug discovery program.
- OpenAI partnered with Novo Nordisk in April on medicine development using the technology.
Those moves matter strategically. If frontier labs treat drug discovery as a first-party business line, startups like Isomorphic must compete for talent, data partnerships, and pharma customers against companies with far larger capital bases. Isomorphic's answer, evidenced by this round, is to raise at a scale that keeps it independent of any single lab's platform.
Why does the $5 billion matter now?
The financing consolidates three trends into one deal. First, AI drug discovery has become the most heavily funded vertical in applied AI, at $23.2 billion raised in 2026 by Dealroom's count. Second, founder-celebrity capital is flowing: Hassabis, the Nobel-recognized architect of modern AI-for-biology research, now commands both the science and the balance sheet. Third, Big Tech remains an anchor investor in the category even as its own labs — OpenAI with Novo Nordisk, Anthropic with its June program — build competing capabilities.
For patients and pharma partners, the near-term test is the one Hassabis named himself: whether Isomorphic's first therapeutic programs actually reach clinical trials. The $5 billion buys the attempt. The next milestone that will define the company is not another raise but a first candidate entering human testing — the step where AI-designed medicine either delivers, as Hassabis put it, "tangible impact for patients" or joins the long list of promising candidates that never clear it.
Source: CNBC Tech
More from Marcus Bennett
Show full bio
Senior reporter covering companies, deals and strategy in artificial intelligence and machine learning at AI In Context.
745 articles
Related articles
- Isomorphic Labs raises $5B to push AI-designed drugs into trials
- Isomorphic Labs raises $5 billion, its second mega-round in six months
- Isomorphic Labs Raises $5B as AI Drug Design Faces Trial Test
- Humyn Labs raises $47M Series A to feed robots real-world data
- INFevo Raises Over RMB 100M to Build AI Virtual Cells and Robotic Labs